Join us in celebrating the remarkable achievements of our July Claspie Award honorees! Congratulations to Mike Maloney, Patricia (Tricia) Fraser, Frank Kamosa, Lenore C., Kate Stokes, Catherine Souza, Alec Andrews, Arman Karim, Amanda Ford, Brena Williams, Julia Shepherd, Angella Ndagire, Kai Li Tan, Kaleigh Krapfl, and Jennifer Ahmed Silva. These exceptional individuals have demonstrated outstanding dedication, creativity, and passion in their roles, truly reflecting the essence of Clasp. Their invaluable contributions drive our success, and we are honored to have them on our team! We deeply appreciate your hard work, collaboration, and unwavering commitment!
About us
Clasp Therapeutics aims to bring absolute precision to immuno-oncology by developing next-generation T cell engagers (TCEs) that target tumor-specific oncogenic driver mutations across hard-to-treat cancers. Clasp is developing T cell engagers to match both the specific characteristics of the patient’s immune system and the specific genetics of their tumor, enabling the creation of exquisitely personalized, yet off-the-shelf, therapeutics. Built upon academic research in the labs of Bert Vogelstein and Drew Pardoll at Johns Hopkins University, Clasp is backed by prominent life sciences investors including Catalio Capital Management, Third Rock Ventures and Novo Holdings. The company was launched in March 2024 and is based in Cambridge, MA and Rockville, MD. For more information about Clasp, please visit www.clasptx.com
- Website
-
www.clasptx.com
External link for Clasp Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Type
- Privately Held
- Founded
- 2020
Employees at Clasp Therapeutics
Updates
-
We are thrilled to welcome Maribel Vazquez, MS, our new Office / Lab Manager & Administrative Assistant, who will lead our lab operations in Rockville. Fun fact: Maribel enjoys reading and listening to audiobooks and sets a reading goal of 40-50 books a year, but in 2022 she read 116 books. Welcome aboard, Maribel! #NewHire #NewClaspian #ClaspTherapeutics
-
-
It's National Black Family Cancer Awareness Week from June 15-21! Join us in spreading awareness, encouraging screenings, and supporting Black families affected by cancer. Together, we can make a difference. 💪🏾❤️ #BlackFamilyCancerAwareness #StrongerTogether
-
-
Clasp Therapeutics recognizes and celebrates Juneteenth! On this day in 1865, two and a half years after President Abraham Lincoln signed the Emancipation Proclamation, union troops freed enslaved African Americans in Galveston Bay. Today, we honor the historical experience and narratives and support the continued empowerment of our Black communities. There are many wonderful ways to celebrate Juneteenth today, such as through art and music, local gatherings, educational forums and supporting Black-owned businesses. We hope everyone has a meaningful day, reflecting on this important milestone of #freedom, #equality, #justice and #resilience. #Juneteenth
-
-
Welcome Laura Bingham, our new Budget and IP Summer Intern. Laura is an accounting student at Christoper Newport University. Fun fact: Laura enjoys the outdoors, especially hiking and horseback riding. Welcome aboard, Laura! #NewHire #ClaspTherapeutics
-
-
At Clasp Therapeutics, we proudly celebrate Pride Month! We honor the resilience, diversity, and achievements of the LGBTQ+ community. Join us in spreading love, acceptance, and equality for all. Happy Pride! 🏳️🌈❤️ #Pride2024 #CelebrateDiversity #EqualityForAll
-
-
Welcome Angella Ndagire, our new Biology Intern and Translational Life Science Technology student at The University of Maryland, who will be working with us this summer. Fun fact: Angella loves the beach and swimming. She once won a "Best Swimmer" award at a local swim club. Welcome aboard, Angella! #NewHire #ClaspTherapeutics
-
-
Congratulations to Amgen on the approval of Tarlatamab in extensive-stage small cell lung cancer (ES-SCLC)! This marks the second T cell engager to receive FDA approval in solid tumors, and a significant leap forward in SCLC treatment. This milestone also energizes our commitment to advancing T cell engager programs in solid tumors. It reminds us of our mission to transform the lives of patients everywhere by mastering the discovery, development and delivery of off-the-shelf precision T cell engagers. #Oncology #CancerResearch #TCellEngagers #SCLC #Amgen #PharmaInnovation #PatientCare
Today, the U.S. FDA approved Amgen’s delta-like ligand 3-targeting Bispecific T-cell Engager (BiTE®) immunotherapy in adults with extensive-stage small cell lung cancer (ES-SCLC). Amgen is proud to deliver the first targeted immunotherapy to this patient population. 🔗 Press release: https://amgen.ly/3X35AWL
-
Please join us in congratulating our outstanding achievers of the month, our April Claspie Award recipients! Catherine Souza, Kate Stokes, Kai Li Tan, Isabella De Leon, Ronald Copeland, Ph.D, and Candice Linde. These individuals have exemplified exceptional dedication, creativity, and passion in their work, embodying the spirit of our organization. Their contributions are integral to our success, and we are proud to have them as part of our team! Thank you for your hard work, teamwork and commitment!
-
-
Clasp celebrates the contributions of Asian Americans and Pacific Islanders to biotech and our world. #AAPIHeritageMonth #ClaspCelebrates
-